Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells

Fig. 6

JNK/c-Jun inhibition and HDAC3 overexpression decrease PD-L1 expression in A549/CDDP cells in vivo. A549 and A549/CDDP and A549/CDDPpReceiver and A549/CDDPHDAC3 cells were injected into the right flanks of nude mice to form xenograft tumors. When the tumor volumes reached ~ 100 mm3, A549/CDDP tumor-bearing mice were treated with PPCES vehicle or SP600125 (15 mg/kg) by intragastrical gavage every 4 days for 2 weeks. The tumors were then collected and digested into single cell suspensions for PD-L1 detection by flow cytometry (a and c), and T cell proliferation assays were performed (b and d). When the volumes of A549/CDDPpReceiver and A549/CDDPHDAC3 tumors reached ~ 1000 mm3, the tumors were collected and digested into single cell suspensions for PD-L1 detection by flow cytometry (e), and T cell proliferation assays were performed (f). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001

Back to article page